Bedrijfsoverzicht
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical entity dedicated to the identification, development, and commercialization of therapeutic medicines for both childhood and adult diseases across the United States. The company operates within the Healthcare sector, specifically functioning in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development aimed at bringing novel treatments to market. As of the latest data, the entity maintains a market capitalization of $2.22B, generates annual revenue of $158.18M, and employs a workforce of 178 individuals. These financial figures indicate that the company has achieved significant scale in its commercial operations, supporting a valuation that is substantial for a biotechnology firm while maintaining a lean operational structure typical of the sector. The combination of a multi-billion dollar market cap and revenue exceeding $150 million suggests the company has successfully transitioned from early-stage research to a phase where product commercialization drives significant financial activity.
Financiële gezondheid
The company reported revenue of $158.18M for the trailing twelve months, yet it recorded a net income of $-107,322,000 and an EBITDA of $-124,274,000, revealing a cost structure where expenses significantly outpace current revenue generation. This disparity between positive revenue and substantial negative net income indicates that operating costs, research and development expenditures, or commercialization expenses are currently consuming the majority of the company's top-line earnings. The free cash flow stands at $-61,958,752, which reflects the cash outflow required to fund ongoing operations and strategic initiatives, highlighting limited financial flexibility in the short term. Margins further illustrate this financial dynamic, with a gross margin of 89.1% suggesting efficient production or sourcing, contrasted by an operating margin of -51.1% and a profit margin of -67.8% that underscore the heavy burden of overhead and R&D costs. The balance sheet shows a robust cash position of $441.11M against a negligible debt load of $2.79M, resulting in a debt-to-equity ratio of 0.63. While the company holds significant liquidity, the current ratio of 8.02 indicates a very strong ability to meet short-term obligations with current assets. However, the return on equity is -22.7% and the return on assets is -14.6%, metrics that reveal that management is currently utilizing shareholder capital to generate losses rather than profits, a common characteristic of growth-stage biotechnology firms.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a P/E ratio (TTM) listed as N/A due to the negative earnings, while the forward P/E is calculated at -502.69. The existence of a negative forward P/E and an unavailable trailing P/E implies that the market is pricing the stock based on future expectations rather than historical profitability, often seen in companies anticipating a turnaround or significant future earnings generation. The price-to-book ratio is 5.01, indicating that the market values the company at five times its book value, which suggests a significant premium assigned to its intangible assets, intellectual property, and growth potential. Alternative valuation metrics such as the price-to-sales ratio of 14.02 and an EV/EBITDA of -14.32 further emphasize that the company is being valued on revenue multiples rather than earnings multiples, typical for firms with negative earnings but high revenue visibility. Regarding trading range, the 52-week high is $21.48 and the 52-week low is $5.63; without a specific current price provided in the facts, the valuation context remains anchored by this wide volatility band. The beta is -1.75, a highly unusual metric for equities that indicates an inverse correlation to the broader market, suggesting the stock's price movements are not standardly aligned with general market indices.
Growth & Income
The company demonstrates robust revenue growth with a year-over-year increase of 83.9%, whereas earnings growth is N/A due to the lack of profitability in the current period. The absence of positive earnings growth relative to revenue expansion implies that while sales are accelerating, the bottom line has not yet benefited proportionally, likely due to the capital-intensive nature of biotechnology development. Regarding income, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since there are no dividends to pay, the company reinvests all available earnings and cash flow directly back into its research, development, and commercialization activities to fuel long-term growth. Consequently, the overall growth and income profile is characterized by high revenue expansion and zero current income distribution, relying entirely on capital appreciation and future earnings potential to deliver value to shareholders.